Boundless Bio, Inc.(BOLD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

BOLD Boundless Bio, Inc.

Closed Good Friday 04-17 16:00:00 EDT

1.42

+0.11

+8.40%

盘后1.42

+0.000.00%

16:53 EDT

High1.44	Low1.27	Vol64.60K
Open1.30	D1 Closing1.31	Amplitude12.98%
Mkt Cap31.66M	Tradable Cap20.15M	Total Shares22.30M
T/O88.69K	T/O Rate0.46%	Tradable Shares14.19M
P/B0.21	ROE-48.21%	EPS-3.85
52wk High12.65	52wk Low1.06	P/E-0.37
Dividend0.00	Div.Yield0.00	ROA-27.23%

Loading ...

Invest in Global Markets with Tiger Brokers!

Open App

{"stockData":{"symbol":"BOLD","market":"US","secType":"STK","nameCN":"Boundless Bio, Inc.","latestPrice":1.42,"timestamp":1744920000000,"preClose":1.31,"halted":0,"volume":64604,"hourTrading":{"tag":"盘后","latestPrice":1.42,"preClose":1.42,"latestTime":"16:53 EDT","volume":473,"amount":675.16,"timestamp":1744923223559},"delay":0,"floatShares":14189975,"shares":22298562,"eps":-3.848504,"marketStatus":"Closed Good Friday","change":0.11,"latestTime":"04-17 16:00:00 EDT","open":1.3,"high":1.44,"low":1.27,"amount":88693.3327872,"amplitude":0.129771,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.848504,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1745222400000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1711598400000,"exchange":"NASDAQ","adjPreClose":1.31,"postHourTrading":{"tag":"盘后","latestPrice":1.42,"preClose":1.42,"latestTime":"16:53 EDT","volume":473,"amount":675.16,"timestamp":1744923223559},"volumeRatio":1.1503356429909266},"requestUrl":"/m/hq/s/BOLD","defaultTab":"news","newsList":[{"id":"2526582573","title":"BILI Social, Part of Allied Energy Inc. (OTC:AGGI), Wins Three Global Awards for Creator-Led Campaigns at BOLD Awards VI","url":"https://stock-news.laohu8.com/highlight/detail?id=2526582573","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526582573?lang=en_us&edition=full_marsco","pubTime":"2025-04-09 05:11","pubTimestamp":1744146660,"startTime":"0","endTime":"0","summary":"BILI Social, a social commerce platform recognized for breakthrough marketing work with clients, Finish  and Dr. Oetker  at international innovation event in Lisbon. BILI Social Wins Three Global Awards for Creator-Led Campaigns at BOLD Awards VI. Adrian Capobianco CEO BILI Social at BOLD Awards VI. MIAMI and TORONTO, April 08, 2025  -- BILI SOCIAL, an indirect subsidiary of Allied Energy Inc , is the social commerce platform redefining how creators and brands connect, made waves on the international scene last week, taking home three awards at a global innovation event in Lisbon, Portugal. The winning campaigns - each rooted in authentic, creator-led content – were developed in partnership with top brands Finish and Giuseppe Pizza .Boldest Sustainability – Finish, “The Torture Test Challenge”BILI partnered with Finish to launch a content-first campaign that tackled tough dish cleaning while also addressing water conservation in a fun, relatable way. This tongue-in-cheek campaign chall","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/bili-social-part-allied-energy-211100333.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4513","BK4085","BK4531","BK4563","BOLD","BK4585","AGGI","BK4588","BK4566","BK4554","BK4526","BK4510","BK4504","BK4077","BK4509","BK4577","BK4503","BK4548","BK4505"],"gpt_icon":1},{"id":"2524548230","title":"Boundless Bio to Participate in the Needham Virtual Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2524548230","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524548230?lang=en_us&edition=full_marsco","pubTime":"2025-04-03 19:00","pubTimestamp":1743678000,"startTime":"0","endTime":"0","summary":"SAN DIEGO, April  03, 2025  (GLOBE NEWSWIRE) -- Boundless Bio(Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/04/03/3054975/0/en/Boundless-Bio-to-Participate-in-the-Needham-Virtual-Healthcare-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BOLD","BK4137","HCSG","BK4139"],"gpt_icon":0},{"id":"2524419464","title":"Analysts Offer Insights on NA Companies: Kyverna Therapeutics, Inc. (KYTX) and Boundless Bio Inc. (BOLD)","url":"https://stock-news.laohu8.com/highlight/detail?id=2524419464","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524419464?lang=en_us&edition=full_marsco","pubTime":"2025-04-03 00:20","pubTimestamp":1743610809,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the NA sector as 2 analysts just weighed in on Kyverna Therapeutics, Inc. (KYTX – Research Report) and Boun...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-na-companies-kyverna-therapeutics-inc-kytx-and-boundless-bio-inc-bold?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-na-companies-kyverna-therapeutics-inc-kytx-and-boundless-bio-inc-bold?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BOLD","BK4141","KYTX","NA","BK4139"],"gpt_icon":0},{"id":"2524124806","title":"Boundless Bio Files $400 Million Mixed Shelf","url":"https://stock-news.laohu8.com/highlight/detail?id=2524124806","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524124806?lang=en_us&edition=full_marsco","pubTime":"2025-04-02 05:02","pubTimestamp":1743541355,"startTime":"0","endTime":"0","summary":"Boundless Bio  filed a mixed shelf registration statement to raise $400 million from the sale of any combination of several securities, according to a Tuesday filing.The filing covers common stock, preferred stock, debt securities, warrants, and units.The sale of the securities will be held \"from time to time,\" the company said.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BOLD","BK4139"],"gpt_icon":0},{"id":"2524864129","title":"BRIEF-Boundless Bio Inc Files For Mixed Shelf Of Up To $400 Million – SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2524864129","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524864129?lang=en_us&edition=full_marsco","pubTime":"2025-04-02 04:08","pubTimestamp":1743538097,"startTime":"0","endTime":"0","summary":"BRIEF-Boundless Bio Inc Files For Mixed Shelf Of Up To $400 Million – SEC FilingApril 1  - Boundless Bio Inc BOLD.O:BOUNDLESS BIO INC FILES FOR MIXED SHELF OF UP TO $400 MILLION – SEC FILINGBOUNDLESS BIO : SALES AGREEMENT PROSPECTUS COVERING OFFERING OF UP TO $14.5 MILLION OF COMMON STOCKSource text: [ID:n0001193125-25-070393]Further company coverage: BOLD.O ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250401:nFWN3QF117:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BOLD"],"gpt_icon":0},{"id":"2524126276","title":"Boundless Bio : Sales Agreement Prospectus Covering Offering of up to $14.5 Million of Common Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2524126276","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524126276?lang=en_us&edition=full_marsco","pubTime":"2025-04-02 04:02","pubTimestamp":1743537770,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250401:nFWN3QF117:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BOLD","BK4139"],"gpt_icon":0},{"id":"2524126223","title":"Boundless Bio Inc Files for Mixed Shelf of up to $400 Mln – SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2524126223","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524126223?lang=en_us&edition=full_marsco","pubTime":"2025-04-02 04:02","pubTimestamp":1743537770,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250401:nFWN3QF117:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BOLD"],"gpt_icon":0},{"id":"2523605420","title":"Guggenheim Sticks to Its Hold Rating for Boundless Bio Inc. (BOLD)","url":"https://stock-news.laohu8.com/highlight/detail?id=2523605420","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523605420?lang=en_us&edition=full_marsco","pubTime":"2025-03-30 21:55","pubTimestamp":1743342904,"startTime":"0","endTime":"0","summary":"Guggenheim analyst Michael Schmidt maintained a Hold rating on Boundless Bio Inc. (BOLD – Research Report) on March 28. The company’s shares closed...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/guggenheim-sticks-to-its-hold-rating-for-boundless-bio-inc-bold?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/guggenheim-sticks-to-its-hold-rating-for-boundless-bio-inc-bold?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BOLD"],"gpt_icon":0},{"id":"2523668733","title":"Boundless Bio’s 2024 Financial Results and Strategic Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2523668733","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523668733?lang=en_us&edition=full_marsco","pubTime":"2025-03-29 12:02","pubTimestamp":1743220977,"startTime":"0","endTime":"0","summary":"Boundless Bio Inc. ( ($BOLD) ) has released its Q4 earnings. Here is a breakdown of the information Boundless Bio Inc. presented to its investors. ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/boundless-bios-2024-financial-results-and-strategic-progress?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/boundless-bios-2024-financial-results-and-strategic-progress?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BOLD","LU2065732104.USD","BK4139","BK4097","PRGS"],"gpt_icon":0},{"id":"2522737175","title":"BRIEF-Boundless Bio Reports Fourth Quarter And Full Year 2024 Financial Results And Business Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2522737175","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522737175?lang=en_us&edition=full_marsco","pubTime":"2025-03-27 19:41","pubTimestamp":1743075696,"startTime":"0","endTime":"0","summary":"BRIEF-Boundless Bio Reports Fourth Quarter And Full Year 2024 Financial Results And Business HighlightsMarch 27 (Reuters) - Boundless Bio Inc BOLD.O:BOUNDLESS BIO REPORTS FOURTH QUARTER AND FULL YEAR ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250327:nTUA2B54XP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BOLD"],"gpt_icon":0},{"id":"2522375428","title":"Boundless Bio Q4 2024 GAAP EPS $(0.74) Beats $(0.77) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2522375428","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522375428?lang=en_us&edition=full_marsco","pubTime":"2025-03-27 19:08","pubTimestamp":1743073681,"startTime":"0","endTime":"0","summary":"Boundless Bio Q4 2024 GAAP EPS $(0.74) Beats $(0.77) Estimate","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/03/44510934/boundless-bio-q4-2024-gaap-eps-0-74-beats-0-77-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BOLD"],"gpt_icon":0},{"id":"2522375436","title":"Boundless Bio Inc: Qtrly Shr Loss $0.74","url":"https://stock-news.laohu8.com/highlight/detail?id=2522375436","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522375436?lang=en_us&edition=full_marsco","pubTime":"2025-03-27 19:00","pubTimestamp":1743073202,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250327:nTUA2B54XP:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BOLD","BK4139"],"gpt_icon":0},{"id":"2522334375","title":"Press Release: Boundless Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2522334375","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522334375?lang=en_us&edition=full_marsco","pubTime":"2025-03-27 19:00","pubTimestamp":1743073200,"startTime":"0","endTime":"0","summary":"BBI-355 Phase 1/2 POTENTIATE trial ongoing in patients with oncogene amplified cancers, with initial proof of concept data expected in the second half of 2025. \"We made important strides in 2024 as we became a public company and continued to advance BBI-355, our oral, selective CHK1 inhibitor in the Phase 1/2 POTENTIATE trial in patients with oncogene amplified cancers, and we look forward to reporting preliminary proof-of-concept data in the second half of this year,\" said Zachary Hornby, President and CEO of Boundless Bio. \"Additionally, we have continued to identify new targets and are advancing an oral degrader of a novel kinesin identified by our Spyglass platform. We are on track to nominate a development candidate for our Kinesin program by mid-year, with the intention to submit an IND in the first half of 2026. We look forward to the year ahead as we continue to advance our pipeline to address the significant unmet need in patients with oncogene amplified cancers.\". BBI-355, a ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BOLD","BK4139"],"gpt_icon":0},{"id":"2521037934","title":"North American Morning Briefing: Stock Futures Fall as Focus Shifts From Fed to Tariffs","url":"https://stock-news.laohu8.com/highlight/detail?id=2521037934","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521037934?lang=en_us&edition=full_marsco","pubTime":"2025-03-21 18:02","pubTimestamp":1742551320,"startTime":"0","endTime":"0","summary":"The euphoria from the Federal Reserve's policy meeting didn't last long.Stock futures were lower Friday as attention shifted from the Fed to the prospect of further tariffs.Trump said in a social media post that the planned imposition of reciprocal tariffs on April 2 would be \"Liberation Day\" in the U.S.\"We maintain our view that the FOMC outcome was effectively a one-day move, with minimal legacy in terms of immediate direction. That said, we also view the FOMC outcome as a whole as nodding towards dovishness, but with numerous caveats,\" ING said.Quantum-computing stocks  are likely to be in focus after suffering steep falls on Thursday as investors appeared unimpressed by their contributions to Nvidia's Quantum Day at its GTC developers' event.The market also faces a test as an estimated $4.5 trillion in options contracts expire, which could increase volatility.FedEx fell 5.1% off hours after it cut its outlook for the year.Lennar management warned investors of a weak housing market.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ET","US5Y.BOND","NVD3.UK","GORV","FBLG","NVDA","SNVD.UK","AFG","NVDD","IMNM","IRD","DXYN","OLMA","US10Y.BOND","US12M.BOND","US30Y.BOND","CCL","US2Y.BOND","NVDY","US7Y.BOND","USAU","FBRX","3NVD.UK","BPTH","PRPH","NVDX","BOLD","XOMA","IMRX","US3Y.BOND","2NVD.UK","DM","NVDS","JVA","ATXI","NVD2.UK","NVDU","US6M.BOND","PURE","MPU","SGMA","ADVM","NGNE","NVDS.UK","NVDL","CKPT","NVIW.SI","ZBIO","SMXT"],"gpt_icon":1},{"id":"2516567677","title":"Press Release: TACO BELL(R) UNVEILS BOLD BUSINESS STRATEGY FOR A RELENTLESSLY INNOVATIVE FUTURE","url":"https://stock-news.laohu8.com/highlight/detail?id=2516567677","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516567677?lang=en_us&edition=full_marsco","pubTime":"2025-03-04 21:19","pubTimestamp":1741094340,"startTime":"0","endTime":"0","summary":"With ambitions to double innovation, the brand is sharing exclusive. -- Taco Bell announces its business growth plan, R.I.N.G. The Bell:. -- After reaching a milestone of $1 billion in operating profit in 2024,Taco Bell launches off last year's momentum to drive double the. -- Ahead of Live Ms LIVE 2025, Taco Bell reveals how it aims to. redefine its global brand experience across menus, service, operations. -- Stay up to date with Live Ms LIVE 2025 on social and. year of innovation on and off the menu, Taco Bell is giving investors. and fans alike even more reason to believe in the brand's magic for. Taco Bell is sharing its business strategy via a unique investor event,the product previews coming tonight at Live Ms LIVE, Taco Bell is. \"People love our brand because we do things differently,\" said Sean. Tresvant, CEO of Taco Bell. \"But we also mean business; we have a strong. strategy that keeps our consumers and restaurant teams top of mind. The. Despite industry-wide headwinds, Taco","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4504","BK4595","LU2133065610.SGD","R","BK4139","LU2265009873.SGD","BK4232","BK4596","BK4585","BOLD","LU1804176565.USD","BK4588","BK4024","BK4516","BK4209","BK4600","STRK","BK4022","TACO","FOR","YUM","BK4023"],"gpt_icon":1},{"id":"2514759839","title":"Boundless Bio to Participate in the Leerink Global Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2514759839","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514759839?lang=en_us&edition=full_marsco","pubTime":"2025-02-26 20:00","pubTimestamp":1740571200,"startTime":"0","endTime":"0","summary":"SAN DIEGO, Feb.  26, 2025  (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/02/26/3032773/0/en/Boundless-Bio-to-Participate-in-the-Leerink-Global-Healthcare-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4137","BK4139","BOLD","HCSG"],"gpt_icon":0},{"id":"2514009958","title":"Wolters Kluwer 2024 Full-Year Report","url":"https://stock-news.laohu8.com/highlight/detail?id=2514009958","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514009958?lang=en_us&edition=full_marsco","pubTime":"2025-02-26 15:00","pubTimestamp":1740553200,"startTime":"0","endTime":"0","summary":"Alphen aan den Rijn, February 26, 2025 – Wolters Kluwer, a global leader in professional information solutions, software and services, today releases its full-year 2024 results.Revenues 5,916 million, up 6% in constant currencies and up 6% organically.Recurring revenues  up 7% organically; non-recurring trends varied.Adjusted operating profit 1,600 million, up 8% in constant currencies.Diluted adjusted EPS 4.97, up 9% overall and up 11% in constant currencies.Adjusted free cash flow 1,276 million, up 9% in constant currencies, ahead of expectation.Net-debt-to-EBITDA of 1.6x; return on invested capital  improved to 18.1%.Proposed 2024 total dividend 2.33 per share, an increase of 12%.Nancy McKinstry, CEO and Chair of the Executive Board, commented: “Wolters Kluwer delivered another year of 6% organic growth and a further increase in the adjusted operating profit margin. Recurring revenues, in particular cloud software subscriptions, continued to be the main driver of our growth. We main","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/wolters-kluwer-2024-full-report-070000393.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["DRIP","H","GHG","LU2236285917.USD","BK4555","LU1721428933.USD","D","J","LU1166156734.SGD","LU0320765646.SGD","BK4106","BK4139","LU2456880835.USD","LU1165135440.EUR","IE00BZ18W340.USD","LU2360032135.SGD","LU2092937221.SGD","LU1201861249.SGD","LU1543694498.USD","BK4567","LU0052756011.USD","K","LU1668664300.SGD","LU0702159343.USD","LU2417539215.USD","ROIC","BK4080","BK4207","BK4585","BK4212","BOLD","F","IE00BSNM7G36.USD","WOLTF","BK4574","CTA","E","LU2125154778.USD","LU0347712357.USD","WTKWY","LU0098860793.USD","BK4156","G","LU0130517989.USD","IE00BN0W2T93.GBP","BK4523","A","LU0477156953.USD","BK4231"],"gpt_icon":0},{"id":"2510308493","title":"IT'S GETTING BOLD: SIMPLY SPIKED ANNOUNCES FIRST-EVER 8% ABV INNOVATION WITH UNAPOLOGETICALLY BOLD ATTITUDE","url":"https://stock-news.laohu8.com/highlight/detail?id=2510308493","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510308493?lang=en_us&edition=full_marsco","pubTime":"2025-02-12 22:10","pubTimestamp":1739369400,"startTime":"0","endTime":"0","summary":"Simply SpikedBold delivers even more flavor and an 8% ABV with two fan-favorite flavors. CHICAGO, Feb. 12, 2025 /PRNewswire/ -- Get ready, Simply Spiked is back and crashing the party with an all-new offering. Introducing Simply Spiked Bold, a line of spiked lemonades and limeades with a bolder flavor and 8% ABV that delivers a new twist on drinking experiences for consumers 21+ nationwide.About Molson Coors Beverage CompanyFor more than two centuries, Molson Coors has brewed beverages that unite people to celebrate all life's moments. From our core power brands Coors Light, Miller Lite, Coors Banquet, Molson Canadian, Carling andOujsko to our above premium brands including Madrí Excepcional, Staropramen, Blue Moon Belgian White and Leinenkugel's Summer Shandy, to our economy and value brands like Miller High Life and Keystone Light, we produce many beloved and iconic beers. While Molson Coors' history is rooted in beer, we offer a mod","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/getting-bold-simply-spiked-announces-141000803.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/getting-bold-simply-spiked-announces-141000803.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0225771236.USD","LU0985481810.HKD","BK4139","IE00B19Z4B17.USD","LU0321505868.SGD","EVER","BK4588","IE00B66KJ199.SGD","LU0306807586.USD","TAP","LU0321505439.SGD","BK4585","BK4077","BK4158","BOLD","IE0031619046.USD","IE00B7SZL793.SGD","LU0225284248.USD","LU0306806265.USD"],"gpt_icon":0},{"id":"2508144689","title":"Boundless Bio appoints Robert Doebele as CMO","url":"https://stock-news.laohu8.com/highlight/detail?id=2508144689","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508144689?lang=en_us&edition=full_marsco","pubTime":"2025-02-03 23:05","pubTimestamp":1738595125,"startTime":"0","endTime":"0","summary":"Boundless Bio (BOLD) announced that Robert Doebele, M.D., Ph.D., has been appointed as Chief Medical Officer. Doebele was the co-founder of Rain On...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/boundless-bio-appoints-robert-doebele-as-cmo?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/boundless-bio-appoints-robert-doebele-as-cmo?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BOLD","BK4139","CMO"],"gpt_icon":0},{"id":"2508408141","title":"Boundless Bio Appoints Robert Doebele, M.d., Ph.d., as Chief Medical Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2508408141","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508408141?lang=en_us&edition=full_marsco","pubTime":"2025-02-03 23:00","pubTimestamp":1738594801,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250203:nTUACDXWPW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BOLD","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.boundlessbio.com","stockEarnings":[{"period":"1week","weight":0.1933},{"period":"1month","weight":-0.1125},{"period":"3month","weight":-0.4387},{"period":"6month","weight":-0.5344},{"period":"1year","weight":-0.8742},{"period":"ytd","weight":-0.5103}],"compareEarnings":[{"period":"1week","weight":0.0035},{"period":"1month","weight":-0.0617},{"period":"3month","weight":-0.1191},{"period":"6month","weight":-0.0995},{"period":"1year","weight":0.0517},{"period":"ytd","weight":-0.1018}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Audentes Therapeutics, Inc., a biotechnology company, focuses on developing and commercializing gene therapy products for patients suffering from diseases caused by single gene defects in the United States. The company is developing four products, including AT132 for the treatment of X-linked myotubular myopathy; AT342 for the treatment of crigler-najjar syndrome type 1; AT307 for the treatment of the CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia; and AT982 for the treatment of pompe disease. Audentes Therapeutics, Inc. has a collaboration with the University of Pennsylvania to develop AT342, an AAV gene therapy for Crigler-Najjar Syndrome, an inherited, metabolic liver disease. The company was founded in 2012 and is based in San Francisco, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.75,"avgChangeRate":0.045467},{"month":2,"riseRate":0.25,"avgChangeRate":0.036219},{"month":3,"riseRate":0.666667,"avgChangeRate":0.088311},{"month":4,"riseRate":0.333333,"avgChangeRate":0.028717},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.032827},{"month":6,"riseRate":1,"avgChangeRate":0.142257},{"month":7,"riseRate":0.666667,"avgChangeRate":0.021175},{"month":8,"riseRate":0.5,"avgChangeRate":-0.031707},{"month":9,"riseRate":0.75,"avgChangeRate":0.116011},{"month":10,"riseRate":0,"avgChangeRate":-0.120737},{"month":11,"riseRate":0.75,"avgChangeRate":0.014772},{"month":12,"riseRate":0.75,"avgChangeRate":0.282026}],"exchange":"NASDAQ","name":"Boundless Bio, Inc.","nameEN":"Boundless Bio, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.33.2","shortVersion":"4.33.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Boundless Bio, Inc.(BOLD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Boundless Bio, Inc.(BOLD) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Boundless Bio, Inc.,BOLD,Boundless Bio, Inc.股票,Boundless Bio, Inc.股票老虎,Boundless Bio, Inc.股票老虎国际,Boundless Bio, Inc.行情,Boundless Bio, Inc.股票行情,Boundless Bio, Inc.股价,Boundless Bio, Inc.股市,Boundless Bio, Inc.股票价格,Boundless Bio, Inc.股票交易,Boundless Bio, Inc.股票购买,Boundless Bio, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Boundless Bio, Inc.(BOLD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Boundless Bio, Inc.(BOLD) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction